Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis

Abstract Background Thymic neuroendocrine tumors comprise a heterogeneous group of rare diseases. This study aimed to investigate the real-world clinicopathological features and treatment outcomes of thymic neuroendocrine tumors. Results A total of 104 patients diagnosed with thymic neuroendocrine t...

Full description

Bibliographic Details
Main Authors: Yeye Chen, Jiaqi Zhang, Mengxin Zhou, Chao Guo, Shanqing Li
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Online Access:https://doi.org/10.1186/s13023-022-02366-x
_version_ 1811258039915773952
author Yeye Chen
Jiaqi Zhang
Mengxin Zhou
Chao Guo
Shanqing Li
author_facet Yeye Chen
Jiaqi Zhang
Mengxin Zhou
Chao Guo
Shanqing Li
author_sort Yeye Chen
collection DOAJ
description Abstract Background Thymic neuroendocrine tumors comprise a heterogeneous group of rare diseases. This study aimed to investigate the real-world clinicopathological features and treatment outcomes of thymic neuroendocrine tumors. Results A total of 104 patients diagnosed with thymic neuroendocrine tumors in a single institution from 1983 to 2021 were eligible. Fourteen (13.46%) and 28 (26.92%) patients diagnosed with thymic neuroendocrine tumors suffered from multiple endocrine neoplasia and ectopic adrenocorticotropic hormone syndrome, respectively. Ninety-seven (93.27%) patients underwent surgical resection, including 79 (81.44%) with radical resection. Except for 5 patients lost during follow-up, the 1-, 3- and 5-year overall survival rates were 91.8%, 70.2% and 54.6%, respectively. The median overall survival was 61.57 months. Multivariate analysis revealed that years at diagnosis (HR 0.559, 95% CI 0.364–0.857, p = 0.008), radical resection (HR 2.860, 95% CI 1.392–5.878, p = 0.004), pathological grade (HR 1.963, 95% CI 1.058–3.644, p = 0.033) and Masaoka–Koga stage (HR 2.250, 95% CI 1.548–3.272, p = 0.000) exerted significant differences in overall survival among 99 patients. In the surgery group, multivariate Cox regression analysis exhibited significant overall survival differences in years at diagnosis (HR 0.563, 95% CI 0.367–0.866, p = 0.009), neoadjuvant therapy (HR 0.248, 95% CI 0.071–0.872, p = 0.030), radical resection (HR 3.674, 95% CI 1.685–8.008, p = 0.001), pathological grade (HR 2.082, 95% CI 1.098–3.947, p = 0.025) and Masaoka–Koga stage (HR 2.445, 95% CI 1.607–3.719, p = 0.000). Conclusions Radical resection and Masaoka–Koga stage were independent prognostic factors for the survival of patients with thymic neuroendocrine tumors. Systemic therapy and integrated management of patients with advanced-stage disease require high-level clinical evidence.
first_indexed 2024-04-12T18:07:09Z
format Article
id doaj.art-3c67ce3386de4b369c1ffe0bf9270306
institution Directory Open Access Journal
issn 1750-1172
language English
last_indexed 2024-04-12T18:07:09Z
publishDate 2022-06-01
publisher BMC
record_format Article
series Orphanet Journal of Rare Diseases
spelling doaj.art-3c67ce3386de4b369c1ffe0bf92703062022-12-22T03:21:57ZengBMCOrphanet Journal of Rare Diseases1750-11722022-06-011711810.1186/s13023-022-02366-xReal-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysisYeye Chen0Jiaqi Zhang1Mengxin Zhou2Chao Guo3Shanqing Li4Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background Thymic neuroendocrine tumors comprise a heterogeneous group of rare diseases. This study aimed to investigate the real-world clinicopathological features and treatment outcomes of thymic neuroendocrine tumors. Results A total of 104 patients diagnosed with thymic neuroendocrine tumors in a single institution from 1983 to 2021 were eligible. Fourteen (13.46%) and 28 (26.92%) patients diagnosed with thymic neuroendocrine tumors suffered from multiple endocrine neoplasia and ectopic adrenocorticotropic hormone syndrome, respectively. Ninety-seven (93.27%) patients underwent surgical resection, including 79 (81.44%) with radical resection. Except for 5 patients lost during follow-up, the 1-, 3- and 5-year overall survival rates were 91.8%, 70.2% and 54.6%, respectively. The median overall survival was 61.57 months. Multivariate analysis revealed that years at diagnosis (HR 0.559, 95% CI 0.364–0.857, p = 0.008), radical resection (HR 2.860, 95% CI 1.392–5.878, p = 0.004), pathological grade (HR 1.963, 95% CI 1.058–3.644, p = 0.033) and Masaoka–Koga stage (HR 2.250, 95% CI 1.548–3.272, p = 0.000) exerted significant differences in overall survival among 99 patients. In the surgery group, multivariate Cox regression analysis exhibited significant overall survival differences in years at diagnosis (HR 0.563, 95% CI 0.367–0.866, p = 0.009), neoadjuvant therapy (HR 0.248, 95% CI 0.071–0.872, p = 0.030), radical resection (HR 3.674, 95% CI 1.685–8.008, p = 0.001), pathological grade (HR 2.082, 95% CI 1.098–3.947, p = 0.025) and Masaoka–Koga stage (HR 2.445, 95% CI 1.607–3.719, p = 0.000). Conclusions Radical resection and Masaoka–Koga stage were independent prognostic factors for the survival of patients with thymic neuroendocrine tumors. Systemic therapy and integrated management of patients with advanced-stage disease require high-level clinical evidence.https://doi.org/10.1186/s13023-022-02366-xThymic neuroendocrine tumorsClinicopathological featuresPrognosis
spellingShingle Yeye Chen
Jiaqi Zhang
Mengxin Zhou
Chao Guo
Shanqing Li
Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis
Orphanet Journal of Rare Diseases
Thymic neuroendocrine tumors
Clinicopathological features
Prognosis
title Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis
title_full Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis
title_fullStr Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis
title_full_unstemmed Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis
title_short Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis
title_sort real world clinicopathological features and outcome of thymic neuroendocrine tumors a retrospective single institution analysis
topic Thymic neuroendocrine tumors
Clinicopathological features
Prognosis
url https://doi.org/10.1186/s13023-022-02366-x
work_keys_str_mv AT yeyechen realworldclinicopathologicalfeaturesandoutcomeofthymicneuroendocrinetumorsaretrospectivesingleinstitutionanalysis
AT jiaqizhang realworldclinicopathologicalfeaturesandoutcomeofthymicneuroendocrinetumorsaretrospectivesingleinstitutionanalysis
AT mengxinzhou realworldclinicopathologicalfeaturesandoutcomeofthymicneuroendocrinetumorsaretrospectivesingleinstitutionanalysis
AT chaoguo realworldclinicopathologicalfeaturesandoutcomeofthymicneuroendocrinetumorsaretrospectivesingleinstitutionanalysis
AT shanqingli realworldclinicopathologicalfeaturesandoutcomeofthymicneuroendocrinetumorsaretrospectivesingleinstitutionanalysis